{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:12:42Z","timestamp":1788581562639,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.vph.2026.107677","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:51:28Z","timestamp":1783921888000},"page":"107677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Aspirin and fibrin clot modulation in vascular pharmacology: Fibrinogen acetylation, disease context, and translational uncertainty"],"prefix":"10.1016","volume":"164","author":[{"given":"Alice","family":"Nerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Nencini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Giurranna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Becatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2026.107677_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109134","article-title":"Regulation of fibrinogen synthesis","volume":"242","author":"Dobson","year":"2024","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2026.107677_bb0010","series-title":"Macromolecular Protein Complexes III: Structure and Function","first-page":"471","article-title":"Fibrinogen and fibrin","author":"Litvinov","year":"2021"},{"key":"10.1016\/j.vph.2026.107677_bb0015","doi-asserted-by":"crossref","DOI":"10.20452\/pamw.15082","article-title":"Congenital structural and functional fibrinogen disorders: a primer for internists","author":"Undas","year":"2019","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.vph.2026.107677_bb0020","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/ATVBAHA.110.213389","article-title":"Molecular mechanisms affecting fibrin structure and stability","volume":"31","author":"Lord","year":"2011","journal-title":"ATVB"},{"key":"10.1016\/j.vph.2026.107677_bb0025","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1016\/j.jtha.2023.08.014","article-title":"Fibrinogen and fibrin: synthesis, structure, and function in health and disease","volume":"21","author":"Wolberg","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2026.107677_bb0030","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2022.25","article-title":"Erythrocyte oxidative stress and thrombosis","volume":"24","author":"Bettiol","year":"2022","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.vph.2026.107677_bb0035","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3389\/fimmu.2019.01085","article-title":"Beh\u00e7et's syndrome as a model of thrombo-inflammation: the role of neutrophils","volume":"10","author":"Emmi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vph.2026.107677_bb0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2018-07-818211","article-title":"The multifaceted role of fibrinogen in tissue injury and inflammation","volume":"133","author":"Luyendyk","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.vph.2026.107677_bb0045","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/antiox14040390","article-title":"Fibrinogen oxidation and thrombosis: shaping structure and function","volume":"14","author":"Nencini","year":"2025","journal-title":"Antioxidants"},{"key":"10.1016\/j.vph.2026.107677_bb0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/ijms23010193","article-title":"Fibrinogen and atherosclerotic cardiovascular diseases\u2014review of the literature and clinical studies","volume":"23","author":"Surma","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.vph.2026.107677_bb0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/cvr\/cvad017","article-title":"Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice","volume":"119","author":"Z\u0105bczyk","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2026.107677_bb0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/biom14020230","article-title":"Comprehensive analysis of the role of fibrinogen and thrombin in clot formation and structure for plasma and purified fibrinogen","volume":"14","author":"Risman","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.vph.2026.107677_bb0065","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/antiox14070825","article-title":"Reactive nitrogen species and fibrinogen: exploring the effects of nitration on blood clots","volume":"14","author":"Nencini","year":"2025","journal-title":"Antioxidants"},{"key":"10.1016\/j.vph.2026.107677_bb0070","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.3390\/ijms22136916","article-title":"Fibrin(ogen) as a therapeutic target: opportunities and challenges","volume":"22","author":"Gaule","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.vph.2026.107677_bb0075","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2019.236901","article-title":"Fibrin(ogen) in human disease: both friend and foe","volume":"105","author":"Vilar","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.vph.2026.107677_bb0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s43556-024-00214-x","article-title":"Post-translational modifications of fibrinogen: implications for clotting, fibrin structure and degradation","volume":"5","author":"Nencini","year":"2024","journal-title":"Mol Biomed"},{"key":"10.1016\/j.vph.2026.107677_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109517","article-title":"Prothrombotic profiles in myelofibrosis: fibrinogen oxidation and the beneficial effects of ruxolitinib","volume":"256","author":"Nencini","year":"2025","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2026.107677_bb0090","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/art.43371","article-title":"Reactive oxygen species-induced modifications of fibrin clots as a link between immune responses and atherothrombosis in systemic lupus erythematosus","volume":"78","author":"Becatti","year":"2026","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2026.107677_bb0095","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.3390\/s24123764","article-title":"Advancing thrombosis research: a novel device for measuring clot permeability","volume":"24","author":"Landi","year":"2024","journal-title":"Sensors"},{"key":"10.1016\/j.vph.2026.107677_bb0100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ejvs.2017.12.002","article-title":"Mechanical and biochemical role of fibrin within a venous thrombus","volume":"55","author":"Chandrashekar","year":"2018","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.vph.2026.107677_bb0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1160\/TH14-01-0032","article-title":"Fibrin clot properties and their modulation in thrombotic disorders","volume":"112","author":"Undas","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2026.107677_bb0110","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.117.308564","article-title":"Fibrinogen and fibrin in hemostasis and thrombosis","volume":"37","author":"Kattula","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2026.107677_bb0115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/10715762.2018.1457217","article-title":"ROS and RNS signalling: adaptive redox switches through oxidative\/nitrosative protein modifications","volume":"52","author":"Moldogazieva","year":"2018","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.vph.2026.107677_bb0120","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3390\/antiox13121456","article-title":"Fibrinogen structural changes and their potential role in endometriosis-related thrombosis","volume":"13","author":"Fini","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.vph.2026.107677_bb0125","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/CIRCRESAHA.120.317789","article-title":"Butyrate-rich diets improve redox status and fibrin lysis in Beh\u00e7et's syndrome","volume":"128","author":"Emmi","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2026.107677_bb0130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/07315724.2018.1445047","article-title":"A Khorasan wheat-based replacement diet improves risk profile of patients with nonalcoholic fatty liver disease (NAFLD): a randomized clinical trial","volume":"37","author":"Dinu","year":"2018","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.vph.2026.107677_bb0135","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3390\/antiox9080737","article-title":"Super-resolution microscopy reveals an altered fibrin network in cirrhosis: the key role of oxidative stress in fibrinogen structural modifications","volume":"9","author":"Becatti","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.vph.2026.107677_bb0140","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jth.12229","article-title":"Fibrin(ogen) and thrombotic disease","volume":"11","author":"Ari\u00ebns","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2026.107677_bb0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2337\/diabetes.51.1.189","article-title":"The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation","volume":"51","author":"Standeven","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.vph.2026.107677_bb0150","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1055\/s-0037-1616055","article-title":"Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin","volume":"86","author":"Siebenlist","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2026.107677_bb0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jth.12455","article-title":"The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis","volume":"12","author":"Hethershaw","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2026.107677_bb0160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2012.03.154","article-title":"Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study","volume":"421","author":"Svensson","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.vph.2026.107677_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1680332","article-title":"Fibrinogen glycosylation and glycation: molecular insights into thrombosis and vascular disease","volume":"12","author":"Borghi","year":"2025","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.vph.2026.107677_bb0170","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.3390\/jcm10204792","article-title":"Glycation and glycosylation in cardiovascular Remodeling: focus on advanced glycation end products and O-linked Glycosylations as glucose-related pathogenetic factors and disease markers","volume":"10","author":"Dozio","year":"2021","journal-title":"JCM"},{"key":"10.1016\/j.vph.2026.107677_bb0175","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/ki.2015.166","article-title":"Protein carbamylation and cardiovascular disease","volume":"88","author":"Verbrugge","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.vph.2026.107677_bb0180","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrneph.2017.103","article-title":"Mechanisms and consequences of carbamoylation","volume":"13","author":"Delanghe","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.vph.2026.107677_bb0185","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1160\/TH16-09-0704","article-title":"Impact of fibrinogen carbamylation on fibrin clot formation and stability","volume":"117","author":"Binder","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2026.107677_bb0190","series-title":"Advances in Clinical Chemistry","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/bs.acc.2022.11.003","article-title":"Protein glycation in diabetes mellitus","author":"Shin","year":"2023"},{"key":"10.1016\/j.vph.2026.107677_bb0195","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1373\/clinchem.2011.163188","article-title":"Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis","volume":"57","author":"Jaisson","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.vph.2026.107677_bb0200","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/ATVBAHA.114.303785","article-title":"Oxidative modification of fibrinogen is associated with altered function and structure in the subacute phase of myocardial infarction","volume":"34","author":"Becatti","year":"2014","journal-title":"ATVB"},{"key":"10.1016\/j.vph.2026.107677_bb0205","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.3390\/ijms26125471","article-title":"Homocysteinylation of fibrinogen: a post-translational link to thrombosis","volume":"26","author":"Giurranna","year":"2025","journal-title":"IJMS"},{"key":"10.1016\/j.vph.2026.107677_bb0210","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s11739-017-1653-5","article-title":"Redox status alterations during the competitive season in \u00e9lite soccer players: focus on peripheral leukocyte-derived ROS","volume":"12","author":"Becatti","year":"2017","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.vph.2026.107677_bb0215","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2021-220859","article-title":"A unique circulating miRNA profile highlights thrombo-inflammation in Beh\u00e7et's syndrome","volume":"81","author":"Emmi","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vph.2026.107677_bb0220","series-title":"International Review of Cell and Molecular Biology","first-page":"267","article-title":"Molecular, cellular, and physiological significance of N-terminal acetylation","year":"2015"},{"key":"10.1016\/j.vph.2026.107677_bb0225","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tibs.2010.09.003","article-title":"Regulation of intermediary metabolism by protein acetylation","volume":"36","author":"Guan","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.vph.2026.107677_bb0230","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.cdd.4401769","article-title":"HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis","volume":"13","author":"Saha","year":"2006","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.vph.2026.107677_bb0235","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.vph.2026.107677_bb0240","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/cb500848p","article-title":"Site-specific reactivity of nonenzymatic lysine acetylation","volume":"10","author":"Baeza","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.vph.2026.107677_bb0245","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1074\/mcp.O116.065219","article-title":"A proteomic approach to analyze the aspirin-mediated lysine acetylome","volume":"16","author":"Tatham","year":"2017","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.vph.2026.107677_bb0250","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0022-3565(25)21331-3","article-title":"Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels","volume":"250","author":"Bjornsson","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.vph.2026.107677_bb0255","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0033-0620(87)90001-6","article-title":"Platelet-inhibitor drugs' role in coronary artery disease","volume":"29","author":"Fuster","year":"1987","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.vph.2026.107677_bb0260","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2165\/00003495-198835020-00005","article-title":"Aspirin in cardiovascular disease","volume":"35","author":"Reilly","year":"1988","journal-title":"Drugs"},{"key":"10.1016\/j.vph.2026.107677_bb0265","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1001\/archinte.162.19.2197","article-title":"Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events","volume":"162","author":"Weisman","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.vph.2026.107677_bb0270","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199405053301808","article-title":"Aspirin as an antiplatelet drug","volume":"330","author":"Wood","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2026.107677_bb0275","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","article-title":"Platelet-active drugs","volume":"119","author":"Patrono","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.vph.2026.107677_bb0280","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ehj.2003.10.013","article-title":"Expert consensus document on the use of antiplatelet agents the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology","volume":"25","author":"Patrono","year":"2004","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2026.107677_bb0285","first-page":"239","article-title":"Dose-dependent influence of acetylsalicylic acid on platelet functions and plasmatic coagulation factors","volume":"5","author":"Loew","year":"1976","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.vph.2026.107677_bb0290","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2006-01-010645","article-title":"Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions","volume":"109","author":"Undas","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.vph.2026.107677_bb0295","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/FJC.0b013e3181953e0f","article-title":"Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis","volume":"53","author":"He","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.vph.2026.107677_bb0300","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/ATVBAHA.109.183707","article-title":"Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system","volume":"29","author":"Ajjan","year":"2009","journal-title":"ATVB"},{"key":"10.1016\/j.vph.2026.107677_bb0305","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2020.11.031","article-title":"Glycation and acetylation sites on fibrinogen in plasma fibrin clot of patients with type 2 diabetes: effects of low-dose acetylsalicylic acid","volume":"198","author":"Bryk","year":"2021","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2026.107677_bb0310","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1749-6632.2001.tb03540.x","article-title":"Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system","volume":"936","author":"He","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.vph.2026.107677_bb0315","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1053\/euhj.1998.1088","article-title":"Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid","volume":"19","author":"Williams","year":"1998","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2026.107677_bb0320","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.thromres.2005.02.007","article-title":"Marked increase of fibrin gel permeability with very low dose ASA treatment","volume":"116","author":"Antovic","year":"2005","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2026.107677_bb0325","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/00001721-199512000-00004","article-title":"The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator","volume":"6","author":"Williams","year":"1995","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.vph.2026.107677_bb0330","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/oxfordjournals.eurheartj.a015070","article-title":"Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient?","volume":"17","author":"Fatah","year":"1996","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2026.107677_bb0335","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/jth.12872","article-title":"Aspirin therapy is associated with less compact fibrin networks and enhanced fibrinolysis in patients with abdominal aortic aneurysm","volume":"13","author":"Bailey","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2026.107677_bb0340","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/ATVBAHA.119.313626","article-title":"Effects of post-translational modifications of fibrinogen on clot formation, clot structure, and fibrinolysis: a systematic review","volume":"40","author":"De Vries","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2026.107677_bb0345","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2003.12.016","article-title":"Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control","volume":"113","author":"Watala","year":"2004","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2026.107677_bb0350","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00125-007-0898-3","article-title":"Aspirin resistance and diabetes mellitus","volume":"51","author":"Ajjan","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.vph.2026.107677_bb0355","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients","volume":"26","author":"Sacco","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.vph.2026.107677_bb0360","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2337\/dc11-1302","article-title":"High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes","volume":"35","author":"Tehrani","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.vph.2026.107677_bb0365","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00109-004-0600-x","article-title":"Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin","volume":"83","author":"Watala","year":"2005","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.vph.2026.107677_bb0370","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1161\/01.ATV.16.8.948","article-title":"Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia","volume":"16","author":"Szczeklik","year":"1996","journal-title":"ATVB"},{"key":"10.1016\/j.vph.2026.107677_bb0375","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","article-title":"Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Beh\u00e7et disease","volume":"133","author":"Becatti","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2026.107677_bb0380","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14397595.2017.1285857","article-title":"Certolizumab pegol treatment in Behcet's disease with different organ involvement: a multicenter retrospective observational study","volume":"27","author":"Lopalco","year":"2017","journal-title":"Mod. Rheumatol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189126000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189126000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:34:31Z","timestamp":1788579271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189126000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":76,"alternative-id":["S1537189126000972"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2026.107677","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin and fibrin clot modulation in vascular pharmacology: Fibrinogen acetylation, disease context, and translational uncertainty","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2026.107677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107677"}}